A Rapid Bead-based Radioligand Binding Assay for the Determination of Target-binding Fraction and Quality Control of Radiopharmaceuticals

Overview

Journal Nucl Med Biol

Publisher Elsevier

Specialties Biology
Nuclear Medicine

Date 2019 May 26

PMID 31128476

Citations 36

Authors

Sai Kiran Sharma

Serge K Lyashchenko

Hijin A Park

NagaVaraKishore Pillarsetty

Yorann Roux

Jiong Wu

Sophie Poty

Kathryn M Tully

John T Poirier

Jason S Lewis

Affiliations

Soon will be listed here.

Abstract

Introduction: Determination of the target-binding fraction (TBF) of radiopharmaceuticals using cell-based assays is prone to inconsistencies arising from several intrinsic and extrinsic factors. Here, we report a cell-free quantitative method of analysis to determine the TBF of radioligands.

Methods: Magnetic beads functionalized with Ni-NTA or streptavidin were incubated with 1 μg of histidine-tagged or biotinylated antigen of choice for 15 min, followed by incubating 1 ng of the radioligand for 30 min. The beads, supernatant and wash fractions were measured for radioactivity on a gamma counter. The TBF was determined by quantifying the percentage of activity associated with the magnetic beads.

Results: The described method works robustly with a variety of radioisotopes and class of molecules used as radioligands. The entire assay can be completed within 2 h.

Conclusion: The described method yields results in a rapid and reliable manner whilst improving and extending the scope of previously described bead-based radioimmunoassays.

Advances In Knowledge: Using a bead-based radioligand binding assay overcomes the limitations of traditional cell-based assays. The described method is applicable to antibody as well as non-antibody based radioligands and is independent of the effect of target antigen density on cells, the choice of radioisotope used for synthesis of the radioligand and the temperature at which the assay is performed.

Implications For Patient Care: The bead-based radioligand binding assay is significantly easier to perform and is ideally suited for adoption by the radiopharmacy as a quality control method of analysis to fulfill the criteria for release of radiopharmaceuticals in the clinic. The use of this assay is likely to ensure a more reliable validation of radiopharmaceutical quality and result in fewer failed doses, which could ultimately translate to an efficient release of radiopharmaceuticals for administration to patients in the clinic.

Citing Articles

Cell Model for Testing Pharmaceuticals Targeting Human PD-L1.

Shashkova O, Terekhina L, Malakhov I, Pinevich A, Vartanyan N, Avrov K Sovrem Tekhnologii Med. 2025; 16(5):5-15.

PMID: 39897068 PMC: 11784882. DOI: 10.17691/stm2024.16.5.01.

Water solubility and folate receptor affinity-driven plasma membrane-targeted carbon dots for cancer cell imaging.

Jin T, Zhang L, Zhao Y, Wang J, Liu Z, Zhang R RSC Adv. 2024; 14(47):34816-34822.

PMID: 39483381 PMC: 11526347. DOI: 10.1039/d4ra03337j.

Imaging PD-L1 in the brain-Journey from the lab to the clinic.

Dar D, Rodak M, Da Pieve C, Gorczewska I, Sharma G, Chmielik E Neuro Oncol. 2024; 27(2):567-582.

PMID: 39470381 PMC: 11812043. DOI: 10.1093/neuonc/noae190.

uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence.

Pratt E, Mezzadra R, Kulick A, Kaminsky S, Samuels Z, Loor A J Nucl Med. 2024; 65(11):1718-1723.

PMID: 39362768 PMC: 11533913. DOI: 10.2967/jnumed.124.268278.

Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting.

Poty S, Ordas L, Dekempeneer Y, Parach A, Navarro L, Santens F J Nucl Med. 2024; 65(10):1564-1570.

PMID: 39266288 PMC: 11448608. DOI: 10.2967/jnumed.124.267624.

References

Sawada R, Sun S, Wu X, Hong F, Ragupathi G, Livingston P . Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res. 2011; 17(5):1024-32. PMC: 3074602. DOI: 10.1158/1078-0432.CCR-10-2640. View

Ulaner G, Hyman D, Ross D, Corben A, Chandarlapaty S, Goldfarb S . Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med. 2016; 57(10):1523-1528. PMC: 5050126. DOI: 10.2967/jnumed.115.172031. View

Geissler F, Anderson S, Venkatesan P, Press O . Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res. 1992; 52(10):2907-15. View

Dux R, Kindler-Rohrborn A, Lennartz K, Rajewsky M . Determination of immunoreactive fraction and kinetic parameters of a radiolabeled monoclonal antibody in the absence of antigen excess. J Immunol Methods. 1991; 144(2):175-83. DOI: 10.1016/0022-1759(91)90084-s. View

Rhodes B, Buckelew J, Pant K, Hinkle G . Quality control test for immunoreactivity of radiolabeled antibody. Biotechniques. 1990; 8(1):70-5. View

Sharma S, Pourat J, Abdel-Atti D, Carlin S, Piersigilli A, Bankovich A . Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Res. 2017; 77(14):3931-3941. PMC: 5534176. DOI: 10.1158/0008-5472.CAN-17-0299. View

Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal S, Guo H . Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. J Biol Chem. 2015; 290(50):30018-29. PMC: 4705981. DOI: 10.1074/jbc.M115.679852. View

Bailey K, Pandit-Taskar N, Humm J, Zanzonico P, Gilheeney S, Cheung N . Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. J Neurooncol. 2019; 143(1):101-106. PMC: 7416633. DOI: 10.1007/s11060-019-03139-6. View

Kramer K, Kushner B, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P . Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2009; 97(3):409-18. PMC: 3533371. DOI: 10.1007/s11060-009-0038-7. View

10.

Zalutsky M, Zhao X, Alston K, Bigner D . High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J Nucl Med. 2001; 42(10):1508-15. View

11.

Vivier D, Sharma S, Zeglis B . Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging. J Labelled Comp Radiopharm. 2018; 61(9):672-692. PMC: 6432633. DOI: 10.1002/jlcr.3628. View

12.

Shih L, Thorpe S, Griffiths G, Diril H, Ong G, Hansen H . The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994; 35(5):899-908. View

13.

Zamora P, Sass K, CARDILLO A, Lambert C, Budd P, Marek M . Affinity thin-layer chromatography test of the immunoreactive fraction of radiolabeled antibodies. Biotechniques. 1994; 16(2):306-11. View

14.

Burvenich I, Schoonooghe S, Cornelissen B, Blanckaert P, Coene E, Cuvelier C . In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model. Clin Cancer Res. 2005; 11(20):7288-96. DOI: 10.1158/1078-0432.CCR-04-2503. View

15.

Mattes M . Limitations of the Lindmo method in determining antibody immunoreactivity. Int J Cancer. 1995; 61(2):286-8. DOI: 10.1002/ijc.2910610224. View

16.

Barendswaard E, Humm J, ODonoghue J, Sgouros G, Finn R, Scott A . Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med. 2001; 42(8):1251-6. View

17.

Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn Jr P . Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984; 72(1):77-89. DOI: 10.1016/0022-1759(84)90435-6. View

18.

Nahta R, Hung M, Esteva F . The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004; 64(7):2343-6. DOI: 10.1158/0008-5472.can-03-3856. View

19.

Viola-Villegas N, Rice S, Carlin S, Wu X, Evans M, Sevak K . Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med. 2013; 54(11):1876-82. PMC: 4274751. DOI: 10.2967/jnumed.113.119867. View